![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
This interactive checklist guides you through 10 critical questions that can help uncover next steps for your health system’s specialty pharmacy strategy.
Good News for Biosimilar Adoption Rates as Pharmacies Find Workable Strategies
Navigating the use of biosimilars with the 340B Drug Pricing Program.
By
Date
January 11, 2022
Read time: 7 minutes
After a slow start, biosimilar adoption rates are trending upward in the United States. According to AmGen, there was a 65% increase in the number of approved biosimilars between 2019-2020 and a 157% increase in available biosimilars in the U.S.
An expert from our 340B Solutions team explains what these biosimilar adoption rates mean for 340B-qualified pharmacies.
Learn more about navigating the use of biosimilars with the 340B Drug Pricing Program.
Related Stories
This interactive checklist guides you through 5 critical questions that can help uncover next steps for your health system’s infusion service line.
Take a look at the industry insights, experience, and expertise you’ll have access to at this year’s ASHP Midyear.
McKesson’s Intrafusion expert discusses the measurable impacts of a successful infusion service line in health systems.
Use this comprehensive library of resources to find important information on what’s changing with 340B and IRA, when, and why it may matter for your health system pharmacy.
An interactive experience highlighting key insights for success across 8 domains of specialty pharmacy.
One of our Specialty Pharmacy Enablement (SPE) experts outlines her three-pronged approach for success and suggests the addition of a critical fourth.
Download this checklist for an at-a-glance view of important considerations when modernizing your health system’s infusion service line.
Our Specialty Pharmacy Enablement (SPE) expert discusses 3 critical areas of access for the health system specialty pharmacy.
One of our McKesson experts discusses the importance of staying informed as 340B changes continue to unfold.